Abstract
Venous thromboembolic disease (VTE) remains the most common and potentially fatal complication following total knee replacement (TKR). Its incidence has been reported in excess of 50% if no prophylaxis is used. Even with current prophylaxis regimens, VTE incidence remains high in the range of 25% to 30%. Three prophylaxis regimens are recommended according to the guidelines put forth by the American College of Chest Physicians: 1) low-molecular-weight heparin, 2) indirect factor Xa inhibitor, and 3) adjusted-dose warfarin. Phase II and III clinical trials are currently underway to evaluate the efficacy and safety of newer antithrombotic agents as prophylaxis against VTE following TKR.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 31-35 |
| Number of pages | 5 |
| Journal | Journal of surgical orthopaedic advances |
| Volume | 16 |
| Issue number | 1 |
| State | Published - 2007 |
ASJC Scopus subject areas
- General Medicine